Enlivex Therapeutics Ltd. (ENLV) Key Statistics & Financial Ratios

Enlivex Therapeutics Ltd. (ENLV) — Price $0.81 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Enlivex Therapeutics Ltd. (ENLV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.

Stock Data

Price$0.81
Market Cap$14M
Enterprise Value$12.3M
Beta1.68
ExchangeNASDAQ
CountryIL

Valuation Multiples

P/E Ratio0.00
Price / Book0.00
P/S0.00
EV/EBITDA-0.86
EV/Sales0.00
EV/FCF-1.11
P/FCF-1.22
Earnings Yield50278.33%
FCF Yield-81.24%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity248.08%
Return on Assets53.10%
Return on Invested Capital-0.49%
Return on Capital Employed-0.65%

Financial Health

Current Ratio193.24
Quick Ratio193.24
Cash Ratio0.22
Debt / Equity0.00
Debt / Assets0.03%
Net Debt / EBITDA0.10
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share638.66
Cash per share1.94
FCF per share-3.66
Tangible Book Value per share446.40
Dividend per share0.00

Related companies: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN

Explore sector: Healthcare · Biotechnology

More sections of ENLV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks